Here's a list of all the authorized Covid 19 therapeutics, broken down by drug name, and then listed by drug type. It's lengthy, so I'll display the links first, for a perhaps easier-to-view presentation.
For the treatment of COVID-19 in hospitalized adults and pediatric patients (2 years of age and older) who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).
05/26/2021 Sotrovimab
For the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.
03/12/2021 Propofol-Lipuro
To maintain sedation via continuous infusion in patients greater than age 16 with suspected or confirmed COVID-19 who require mechanical ventilation in an ICU setting.
02/09/2021 Bamlanivimab and Etesevimab (344KB) (Reissued February 25, 2021)
Pause in distribution of bamlanivimab/etesevimab nationwide
For the treatment of mild-to-moderate COVID-19 in adult and pediatric patients with positive results of direct SARS-CoV-2 viral testing who are 12 years of age and older weighing at least 40 kilograms (about 88 pounds), and who are at high risk for progressing to severe COVID-19 and/or hospitalization.
11/21/2020 REGEN-COV (Casirivimab and Imdevimab) (378KB) (Reissued February 3, 2021, February 25, 2021 and June 3, 2021)
Casirivimab and imdevimab to be administered together for the treatment of mild to moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progressing to severe COVID-19 and/or hospitalization.
11/19/2020 Baricitinib (Olumiant) in Combination with remdesivir (Veklury)
For emergency use by healthcare providers for the treatment of suspected or laboratory-confirmed COVID-19 in hospitalized adults and pediatric patients 2 years of age or older requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).
08/23/2020 COVID-19 convalescent plasma (285KB) (Reissued February 23, 2021 and March 9, 2021)
Letter Granting EUA Amendment (June 2, 2021)
For the treatment of hospitalized patients with Coronavirus Disease 2019 (COVID-19)
08/13/2020 REGIOCIT replacement solution that contains citrate for regional citrate anticoagulation (RCA) of the extracorporeal circuit
To be used as a replacement solution only in adult patients treated with continuous renal replacement therapy (CRRT), and for whom regional citrate anticoagulation is appropriate, in a critical care setting
05/08/2020 Fresenius Kabi Propoven 2%
To maintain sedation via continuous infusion in patients older than age 16 with suspected or confirmed COVID-19 who require mechanical ventilation in an ICU setting
05/01/2020 Remdesivir for Certain Hospitalized COVID-19 Patients (423KB) (Reissued August 28, 2020, October 1, 2020, and October 22, 2020)
For emergency use by licensed healthcare providers for the treatment of suspected or laboratory-confirmed COVID-19 in hospitalized pediatric patients weighing 3.5 kg to less than 40 kg or hospitalized pediatric patients less than 12 years of age weighing at least 3.5 kg.
On October 22, 2020, FDA approved Veklury (remdesivir) for use in adults and pediatric patients (12 years of age and older and weighing at least 40 kg) for the treatment of COVID-19 requiring hospitalization. Veklury should only be administered in a hospital or in a healthcare setting capable of providing acute care comparable to inpatient hospital care. This approval does not include the entire population that had been authorized to use Veklury under an Emergency Use Authorization (EUA) originally issued on May 1, 2020. In order to ensure continued access to the pediatric population previously covered under the EUA, the EUA for Veklury continues to authorize Veklury for emergency use by licensed healthcare providers for the treatment of suspected or laboratory-confirmed COVID-19 in hospitalized pediatric patients weighing 3.5 kg to less than 40 kg or hospitalized pediatric patients less than 12 years of age weighing at least 3.5 kg.
04/30/2020 Fresenius Medical, multiFiltrate PRO System and multiBic/multiPlus Solutions
To provide continuous renal replacement therapy (CRRT) to treat patients in an acute care environment during the COVID-19 pandemic.
All of the above COVID-19 Therapeutics listed by drug type
SARS-COV-2-targeting Monoclonal Antibodies REGEN-COV (Casirivimab and Imdevimab) Sotrovimab Bamlanivimab and Etesevimab
News 
Market Data 
Discover 
